- Immix Biopharma ( NASDAQ: IMMX ) is trading ~7% higher premarket after it announced patient dosing in an ongoing Phase 1b/2a IMX-110 monotherapy clinical trial.
- The company expects IMX-110 clinical trial data to be released on a rolling basis beginning in Q1 2023.
- Once dosing begins, patients undergo CT scans every 8 weeks to assess tumor response to IMX-110, under the trial.
- The company is also testing IMX-110 as a combination therapy with Beigene/Novartis anti-PD-1 tislelizumab.
For further details see:
Immix Biopharma rises 7% on patient dosing in phase 1b/2a IMX-110 monotherapy trial